However, several studies have shown that GLS2 is highly expressed in triple-negative basal-like breast cancer (TNBC) and metastatic lung cancer and that it confers radioresistance in advanced human cervical cancer cells, suggesting that GLS2 may reduce reactive oxygen species (ROS) levels by increasing the level of cellular reduced glutathione (GSH), NADH, or NADPH14–16. The gene discussed is GLS2; the disease is breast carcinoma.